Menu
October 20, 2023 : Centhaquine, a novel drug candidate for treating Alzheimer’s disease (AD), is set to enter a Phase 3 clinical trial in the US and Europe. The trial has been approved by the US Food and Drug Administration (FDA).
The Phase 3 trial is a randomized, double-blind, placebo-controlled trial that will enroll approximately 1,000 patients with mild to moderate AD. The trial will assess the safety and efficacy of centhaquine in slowing AD progression.
Centhaquine is a highly selective and potent inhibitor of tau aggregation. Tau aggregation is a key pathological feature of AD. In preclinical studies, Centhaquine has been shown to reduce tau aggregation and improve cognitive function.
The Phase 3 trial is a major milestone in the development of centhaquine. If the trial succeeds, centhaquine could become the first new drug approved for AD treatment in over two decades.
The Phase 3 trial of centhaquine is a highly anticipated event for the AD community. AD is a devastating disease that affects millions of people worldwide. There is no cure for AD, and the available treatments only provide modest symptomatic relief.
Centhaquine has the potential to be a first-in-class drug for the treatment of AD. Centhaquine targets the underlying cause of AD, tau aggregation. If the Phase 3 trial is successful, centhaquine could provide a much-needed new treatment option for people with AD.
The Phase 3 trial is also a major milestone for the company developing centhaquine. If the trial is successful, the company could become a leader in developing new treatments for AD.
The Phase 3 trial of centhaquine is a major milestone in developing a new treatment for AD. If the trial succeeds, centhaquine could become the first new drug approved for AD treatment in over two decades.
Centhaquine, a new drug for Alzheimer’s disease, is about to start a large clinical trial in the US and Europe. The trial has been approved by the US Food and Drug Administration (FDA).
The trial will involve about 1,000 people with mild to moderate Alzheimer’s disease. It will compare centhaquine to placebo to see if it is safe and effective in slowing disease progression.
Centhaquine has the potential to be a first-in-class drug for the treatment of Alzheimer’s disease. It targets the underlying cause of the disease, which is the buildup of a protein called tau. If the trial is successful, centhaquine could provide a much-needed new treatment option for people with Alzheimer’s disease.
